Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
OptiBiotix Health said subsidiary ProBiotix Health had completed process validation under pharmaceutical good manufacturing practices for its probiotic product as a drug substance.
The company had also received a letter from the US Food and Drug Administration affirming the product's generally recognized as safe status.
'Few marketed probiotics have achieved this level of proven safety and efficacy and it has triggered another milestone payment in the US pharmaceutical agreement we announced last year,' chief executive Steve Prescott said.